eur op eanexhibitionofcreati vityandinnovation - Europe Direct Iasi

EUROINVENT 2013
National Research&Development Institute for Chemistry
and Petrochemistry - ICECHIM Bucharest
38.1
Title
Authors
Institution
Patent no.
Description
Class
Use of Tetrasulphonated Porphyrin for Manufacturing a
Photosensitization Agent to be Used in Dermatologic
Therapy
Rodica-Mariana Ion, Monica Teodora Neagu, Carolina
Constantin, Daniel Boda
ICECHIM – Bucharest
INCD “Victor Babes” Institute, Bucharest
Colentina Hospital, Bucharest
RO125082/2010
The invention relates to the use of porphyrins - 5,10,15,20-tetra-kisp-sulfonato-phenyl-porphyrin
(TPPS4) in acid form, for the
manufacture of a photosensitizing agent for the treatment of actinic
keratoses. There are various known photosensitizing agent in the
treatment of several dermatological disorders (benign or malignant),
the most known being 5-aminolevulinic acid (5-ALA). However,
anti-tumor therapy with 5-ALA photodynamic reduces moderately
(45%) the tumor volume and recorded numerous adverse effects:
thermal and photochemical instability, temporal effect of up to two
years, local edema, erythema, ulceration and reactions
photosensitivity skin about 1-2 weeks low penetration of the
epidermis and moderate tumor selectivity. Photosensitizing agent
according to the invention TPPS4 has photodynamic action in
actinic keratoses, can replace 5-ALA, is thermally stable in both
acidic and basic environments, and is able to produce tumor
necrosis in the affected areas, do not show adverse effects and have
not toxicity. Also there is no mention of literature on the use of
TPPS4 in actinic keratoses. Actinic keratoses are also known as
solar keratoses. Spots are characterized by small red, with sizes
between 2 and 6 mm in diameter, which appear on the skin after
prolonged exposure to sunlight and dissapear after topically
administered TPPS4 at the patients.
4. Medicine - Health Care - Cosmetics
NATIONAL
210